A number of other brokerages also recently weighed in on REGN. ValuEngine upgraded Regeneron Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, December 17th. Bank of America started coverage on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 16th. They issued a neutral rating and a $325.00 price target for the company. Cowen set a $349.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a hold rating in a report on Tuesday, October 8th. Citigroup raised shares of Regeneron Pharmaceuticals from a neutral rating to a buy rating and boosted their price objective for the company from $340.00 to $420.00 in a research report on Wednesday, November 6th. Finally, Oppenheimer dropped their price target on shares of Regeneron Pharmaceuticals from $480.00 to $430.00 in a research note on Wednesday, November 6th. Twelve investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of $389.05.
Shares of REGN stock opened at $385.94 on Friday. The firm has a market capitalization of $42.37 billion, a PE ratio of 20.66, a price-to-earnings-growth ratio of 1.06 and a beta of 1.20. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.27 and a current ratio of 4.03. Regeneron Pharmaceuticals has a 1 year low of $271.37 and a 1 year high of $442.00. The stock has a fifty day moving average of $374.64 and a two-hundred day moving average of $322.22.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported $6.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $5.13 by $1.54. Regeneron Pharmaceuticals had a net margin of 28.13% and a return on equity of 24.85%. The business had revenue of $2.05 billion for the quarter, compared to analyst estimates of $1.98 billion. During the same quarter in the previous year, the business earned $5.87 earnings per share. The firm’s revenue was up 23.2% compared to the same quarter last year. Equities research analysts predict that Regeneron Pharmaceuticals will post 20.26 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals announced that its board has initiated a share repurchase program on Tuesday, November 5th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the biopharmaceutical company to repurchase up to 2.9% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its shares are undervalued.
In other Regeneron Pharmaceuticals news, EVP Neil Stahl sold 7,364 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $338.52, for a total value of $2,492,861.28. Following the sale, the executive vice president now owns 21,150 shares of the company’s stock, valued at approximately $7,159,698. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $340.44, for a total value of $340,440.00. Following the completion of the sale, the director now directly owns 10,323 shares in the company, valued at approximately $3,514,362.12. The disclosure for this sale can be found here. Insiders have sold a total of 109,543 shares of company stock worth $40,357,770 over the last 90 days. Corporate insiders own 11.84% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Raymond James Trust N.A. increased its stake in Regeneron Pharmaceuticals by 3.4% during the 4th quarter. Raymond James Trust N.A. now owns 798 shares of the biopharmaceutical company’s stock worth $300,000 after acquiring an additional 26 shares during the period. Zeke Capital Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 2.8% in the fourth quarter. Zeke Capital Advisors LLC now owns 1,263 shares of the biopharmaceutical company’s stock worth $474,000 after purchasing an additional 34 shares during the period. Victory Capital Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 0.5% in the second quarter. Victory Capital Management Inc. now owns 7,941 shares of the biopharmaceutical company’s stock worth $2,486,000 after purchasing an additional 38 shares during the period. Summit X LLC increased its position in shares of Regeneron Pharmaceuticals by 5.2% in the third quarter. Summit X LLC now owns 1,100 shares of the biopharmaceutical company’s stock worth $310,000 after purchasing an additional 54 shares during the period. Finally, Venturi Wealth Management LLC raised its stake in Regeneron Pharmaceuticals by 8.4% in the third quarter. Venturi Wealth Management LLC now owns 711 shares of the biopharmaceutical company’s stock valued at $197,000 after purchasing an additional 55 shares in the last quarter. 66.43% of the stock is owned by institutional investors.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Recommended Story: S&P 500 Index
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.